$ardx: great report, +20% in 3-4 days +57% in 1-2 weekNASDAQ:ARDX
+20% in 3-4 days
+57% in 1-2 week
Quoter report is very good, double digits revenue growth, a lot of insiders buys
21.02 expiration day for options. By now - it is mostly calls 6usd (6000 pc)
As soon calls option will expire have to be all shorts closed
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.64 MXN
−815.96 M MXN
6.96 B MXN
231.12 M
About Ardelyx, Inc.
Sector
Industry
CEO
Michael G. Raab
Website
Headquarters
Waltham
Founded
2007
FIGI
BBG01GG14FX9
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
ARDX Channel breakout NASDAQ:ARDX Channel break is all based on business performance. If good Q3 ER = 60+mm rev// neg .05-.07 eps (27-X/35-I/ 3-ect ) then breakout. If neutral or flatish growth, then more development, sales, and catalyst needed.. develops into Elliot 5 wave in the channel. Could break on good #4 too, bu
ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X:
Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week,
I would consider purchasing the 4usd strike price Calls with
an expiration date of 2024-1-19,
for a premium of approximately $0.45.
If t
Focus on Biotechnology: Ardelyx Inc. Trading Idea for 19/10/2023Biotechnology company Ardelyx Inc. has received FDA approval for its drug Xphozah. This medication is intended for treating kidney diseases and is typically recommended for patients with elevated kidney phosphorus levels. Xphozah could be a valuable addition to hemodialysis therapy since it is compa
ARDX: Buy ideaBuy idea on ARDX as you see on the chart after the breakout with force the vwap indicator and the resistance line by a big green candle with a large green volume. In other hand, we will have a reversal trend if we have the breakout with force the support line by a big red candle with a large red vol
ARDX Strong upgrade from a top financial firmARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of ARDX is 64.40 MXN — it has decreased by −3.16% in the past 24 hours. Watch ARDELYX, INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange ARDELYX, INC stocks are traded under the ticker ARDX.
ARDX stock has fallen by −39.92% compared to the previous week, the month change is a −39.92% fall, over the last year ARDELYX, INC has showed a −44.01% decrease.
We've gathered analysts' opinions on ARDELYX, INC future price: according to them, ARDX price has a max estimate of 293.94 MXN and a min estimate of 107.78 MXN. Watch ARDX chart and read a more detailed ARDELYX, INC stock forecast: see what analysts think of ARDELYX, INC and suggest that you do with its stocks.
ARDX stock is 3.26% volatile and has beta coefficient of 0.36. Track ARDELYX, INC stock price on the chart and check out the list of the most volatile stocks — is ARDELYX, INC there?
Today ARDELYX, INC has the market capitalization of 18.72 B, it has decreased by −9.25% over the last week.
Yes, you can track ARDELYX, INC financials in yearly and quarterly reports right on TradingView.
ARDELYX, INC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
ARDX earnings for the last quarter are −3.48 MXN per share, whereas the estimation was −2.29 MXN resulting in a −51.98% surprise. The estimated earnings for the next quarter are −2.32 MXN per share. See more details about ARDELYX, INC earnings.
ARDELYX, INC revenue for the last quarter amounts to 1.52 B MXN, despite the estimated figure of 1.60 B MXN. In the next quarter, revenue is expected to reach 1.61 B MXN.
ARDX net income for the last quarter is −842.92 M MXN, while the quarter before that showed 96.85 M MXN of net income which accounts for −970.38% change. Track more ARDELYX, INC financial stats to get the full picture.
No, ARDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 21, 2025, the company has 395 employees. See our rating of the largest employees — is ARDELYX, INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARDELYX, INC EBITDA is −766.04 M MXN, and current EBITDA margin is −7.76%. See more stats in ARDELYX, INC financial statements.
Like other stocks, ARDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARDELYX, INC stock right from TradingView charts — choose your broker and connect to your account.